Safety of Linagliptin in Patients with Liver Disease and Pancreatic Disease

Introduction to Linagliptin Safety

• The American Diabetes Association recommends linagliptin as a safe option for patients with liver disease, as it does not require dose adjustment in hepatic impairment, but should be used with caution in patients with a history of pancreatic disease due to reports of pancreatitis with DPP-4 inhibitors 1

Linagliptin and Liver Disease

• Linagliptin does not cause hepatotoxicity as a primary concern, unlike some other antidiabetic medications, according to the American Association of Clinical Endocrinologists 2

Linagliptin and Pancreatic Disease

• The FDA recommends discontinuing DPP-4 inhibitors if pancreatitis is suspected, and linagliptin is no exception, as stated by the American College of Gastroenterology 1
• Pancreatitis has been reported with DPP-4 inhibitors, including linagliptin, although causality has not been definitively established, as noted by the American Gastroenterological Association 1, 2

Renal Considerations

• Linagliptin does not require dose adjustment in patients with renal impairment, making it a suitable option for patients with both liver disease and kidney dysfunction, according to the National Kidney Foundation 1, 3, 4
• The American College of Cardiology recommends considering linagliptin for patients with renal impairment due to its favorable pharmacokinetic profile 4